OncoMatch/Clinical Trials/NCT06414954
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Is NCT06414954 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies NMD670 for myasthenia gravis.
Treatment: NMD670 — This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CHRNA1 antibody positive
Documented positive AChR or MuSK antibody test.
Required: MUSK antibody positive
Documented positive AChR or MuSK antibody test.
Performance status
MGFA 2–4
Prior therapy
Cannot have received: investigational medical product
Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Profound Research LLC · Carlsbad, California
- University of California Irvine Medical Center · Irvine, California
- University of Colorado Neuromuscular Division · Aurora, Colorado
- SFM Clinical Research, LLC · Boca Raton, Florida
- Neuromuscular Research Division | University of South Florida · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06414954 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational medical product disqualifies patients from enrollment.
Does this trial require CHRNA1?
Yes, CHRNA1 antibody positive is a required biomarker for enrollment.
Does this trial require MUSK?
Yes, MUSK antibody positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify